Occurrence of the physonect siphonophore Apolemia uvaria (Lesueur, 1815) off Plymouth and in south-west England

In September 2007, observations were made of a siphonophore in surface waters and near to the seabed by sea users off south Devon and south-east Cornwall. The same siphonophore was also recorded from regular samples collected offshore of Plymouth. The species is identified as Apolemia uvaria, which had not previously been recorded off Plymouth. It was sampled until March 2008 and re-appeared, in smaller numbers, in autumn 2008 until February 2009 but was not reliably reported in autumn 2009 (to end of October). The occurrence is unlikely to be due to sea warming, but more likely some variation in oceanic currents, possibly influxes of Atlantic wate

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.

Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine - most notably, oncology and cardiovascular diseases - allowing rapid early detection and supporting the evolution of biomarker-guided, precision-medicine-based targeted therapies. In Alzheimer disease (AD), breakthroughs in biomarker identification and validation include cerebrospinal fluid and PET markers of amyloid-β and tau proteins, which are highly accurate in detecting the presence of AD-associated pathophysiological and neuropathological changes. However, the high cost, insufficient accessibility and/or invasiveness of these assays limit their use as viable first-line tools for detecting patterns of pathophysiology. Therefore, a multistage, tiered approach is needed, prioritizing development of an initial screen to exclude from these tests the high numbers of people with cognitive deficits who do not demonstrate evidence of underlying AD pathophysiology. This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic-industry co-development pathway from identification and assay development to validation for clinical use.I recieved an honorarium from Roche Diagnostics for my participation in the advisory panel meeting leading to this pape